FM
NBIX icon

Forward Management’s Neurocrine Biosciences NBIX Stock Holding History

Forward Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-41,200
Closed -$1.08M – 292
2015
Q2 		$1.08M Buy
41,200
+200
+0.5% +$8.48K 0.07% 168
2015
Q1 		$945K Buy
+41,000
New +$1.47M 0.06% 175
2013
Q4 		– Sell
-25,000
Closed -$283K – 397
2013
Q3 		$283K Sell
25,000
-37,100
-60% -$510K 0.02% 287
2013
Q2 		$740K Buy
+62,100
New +$763K 0.06% 169

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Forward Management's NBIX Position: Q3 2015 in Review

Forward Management sold out of Neurocrine Biosciences (NBIX) in Q3 2015, closing a stake of 41,200 shares — an estimated $1.08M sold.

Forward Management first reported a position in NBIX in Q2 2013 and held it in 4 quarters. The position peaked at $1.08M in Q2 2015. 207 funds tracked by Wall St. Rank hold NBIX as of Q3 2015.

  • Forward Management reported no remaining Neurocrine Biosciences position as of Q3 2015 after selling out during the quarter.
  • Forward Management sold 41,200 Neurocrine Biosciences shares in Q3 2015, an estimated $1.08M.
  • Forward Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 4 quarters.
  • Forward Management's Neurocrine Biosciences position peaked at $1.08M in Q2 2015.
  • 207 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2015.

Based on Forward Management's 13F filing for Q3 2015, filed 9 Nov 2015.